Sign In
Buy DRTS
$10.03
+0.250 (+2.56%)
At Close: Jun 22, 2026
Alpha Tau Medical: A Lot Of Shots On Goal
08:13am, Friday, 12'th Jun 2026
Alpha Tau Medical (DRTS) is pioneering localized alpha particle radiation for solid tumors, with strong recent clinical and partnership momentum. DRTS's innovative and patented "Alpha DaRT" technology
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
08:30am, Wednesday, 03'rd Jun 2026
- Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates
- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of thre
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
09:04am, Friday, 29'th May 2026
Alpha Tau Medical NASDAQ: DRTS outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the compa
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
04:01pm, Monday, 18'th May 2026
- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of pat
Alpha Tau to Participate in May Investor Conferences
08:30am, Monday, 18'th May 2026
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT�
Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally
12:06pm, Monday, 11'th May 2026
Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) rose Monday after the company reported interim results from its U.S. trial of Alpha DaRT in patients with recurrent glioblastoma.
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
10:09am, Monday, 11'th May 2026
Alpha Tau Medical NASDAQ: DRTS presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical
- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
09:10am, Friday, 08'th May 2026
JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT
- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute
09:00am, Thursday, 07'th May 2026
First patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at the world-renowned Pancreas Institute of the University of Verona The study is the first
Alpha Tau Reports 100% Local Disease Control in Early Pancreatic Cancer Data as Program Gains Momentum (DRTS)
01:30pm, Tuesday, 05'th May 2026
WSW, NY, May 5th, 2026, FinanceWireAlpha Tau Medical (NASDAQ: DRTS) reported a striking result in pancreatic cancer: every patient who could be evaluated in two
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT®
